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Abstract
It is anticipated that as the range of drugs for which pharmacogenetic testing becomes available
expands, primary care physicians (PCPs) will become major users of these tests. To assess their
training, familiarity, and attitudes toward pharmacogenetic testing in order to identify barriers to
uptake that may be addressed at this early stage of test use, we conducted a national survey of a
sample of PCPs. Respondents were mostly white (79%), based primarily in community-based
primary care (81%) and almost evenly divided between family medicine and internal medicine.
The majority of respondents had heard of PGx testing and anticipated that these tests are or would
soon become a valuable tool to inform drug response. However, only a minority of respondents
(13%) indicated they felt comfortable ordering PGx tests and almost a quarter reported not having
any education about pharmacogenetics.
CONCLUSIONS—Our results indicate that primary care practitioners envision a major role for
themselves in the delivery of PGx testing but recognize their lack of adequate knowledge and
experience about these tests. Development of effective tools for guiding PCPs in the use of PGx
tests should be a high priority.
INTRODUCTION
Genetic variation has been estimated to account for 20 to 95% of the variation in individual
responses to medications (1) and many different gene variants have been identified that
influence medication response. These findings provide the basis for pharmacogenetic (PGx)
testing, the use of genetic tests to determine the optimal pharmaceutical therapy for a given
individual patient. This testing approach is considered to be one of the most promising early
clinical applications arising from genomics research, with the potential to reduce adverse
drug responses and improve drug efficacy. Drug safety is a particularly important target for
PGx testing since adverse drug reactions are responsible for about 7% of all hospital
admissions and substantially higher proportion for elderly patients (2–5).
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The routine use of PGx testing has been slow due to several reasons including lack of
knowledge and guidelines, little evidence of clinical utility and cost-effectiveness of the test,
delay of treatment, availability of alternative treatments, discrimination and ethical concerns
(6–12). Several studies have documented physicians’ limited knowledge of genetics, genetic
testing, and personalized medicine (13–15) including PGx testing (16–21). Despite
physicians’ limited knowledge, they have expressed interest in using new technologies to
improve therapeutic decision-making (19, 22, 23) though do not appear to be actively
preparing for the use of these tests. In contrast, clinical geneticists and pharmacists have
both begun to address issues related to the use of PGx testing, including assessing
educational needs (24–27), developing educational programs (28–30), defining roles (25, 31,
32), and developing guidelines (33,34) and delivery systems (35–39).
Although PGx tests may be ordered by physicians across a range of medical specialties,
primary care physicians (PCPs) will be a major source of information for patients and will
potentially utilize a number of PGx tests, given the broad range of conditions they routinely
treat. About one-fourth of outpatients are estimated to be taking medications that contain
PGx information in their labels, most prescribed by PCPs (40, 41). Therefore, we sought
their views on their willingness and readiness to utilize PGx testing, desirable test properties,
and factors relevant to the use of PGx tests.
METHODS
Survey Development
The survey was developed through a collaborative effort between investigators at Duke
University’s Institute for Genome Sciences & Policy and the Survey Research Unit at the
University of North Carolina, Chapel Hill. The survey questions were based on a literature
review and focus groups study of health professionals (18).
Survey Pre-testing
To evaluate understandability and the ability of respondents to complete the questions as
intended, a panel of primary care practitioners pre-tested the survey by completing an online
survey evaluation noting confusing questions and ambiguous terms and reporting confidence
in answering questions accurately. The resulting survey was comprised of six major parts,
totaling 101 questions (see Supplemental Materials). In this paper, we report findings from
the first five sections of the survey.
Sampling methods
The sample was obtained from the American Medical Association (AMA) Physician
Masterfile through Direct Medical Data, LLC (Des Plaines, IL). A random sample of
physicians meeting the following criteria was requested: 1) board-certified in either Family
Medicine or Internal Medicine but not board-certified in a sub-specialty; 2) hold a license to
practice in their state of residence; and 3) graduated between 1970 and 2003, thus excluding
physicians who are likely to be over the age of 65 and retired. A total of 4,000 names (2,000
per frame) were randomly selected from the community of internists (n=47,348) and family
medicine practitioners (n=47,179). The samples were stratified by census regions to ensure
representation from the midwest, northeast, south and west.
Data Collection
To guarantee that the frame data received from the vendor was correct, the SRU screened
each case by telephone to verify physician name, mailing address, and eligibility status. In
addition to the sample criteria, physicians also needed to be practicing and actively seeing
patients to be eligible to complete the survey. Out of the 4,000 physicians sampled, 829
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could not be screened because contact information provided by the vendor was inaccurate
and correct information could not be found, 70 cases were ineligible, and 56 cases directly
refused participation. The initial round of screening achieved a contact rate of 76%
(3045/4000).
The survey was conducted from November 19, 2010 to April 15, 2011. The mode of data
collection included a mailed survey invitation and questionnaire along with a letter of
support from the President of the American Academy of Family Physicians (L.Heim) or the
past President of the Society of General Internal Medicine (E. Rich) with a postage-paid
return envelope. Non-respondents were followed up via telephone, fax, and mailings. The
study was approved by the Institutional Review Boards at Duke University Medical Center
and the University of North Carolina, Chapel Hill. Respondents who completed the survey
were provided $35.
Of 3,045 confirmed names/addresses, 597 completed the survey, three were determined to
be ineligible, and 2,445 did not respond, yielding a cooperation rate of 20% (597/3042). The
response rate, 15%, was determined by multiplying the contact rate by the cooperation rate
(76% • 20%).
Data Analysis
Sample weights were produced as the inverse of stratum-specific sampling rates and then
adjusted for differential nonresponse per stratum to improve nationwide coverage. Final
weights were post-stratified on population counts as provided by the AMA Physician
Masterfile based on specialty (internal vs. family medicine), gender (male vs. female), and
year of graduation from medical school (≤1980, 1981–1990, 1991–2000, ≥2001). Estimates
were weighted and a 95% confidence bound is provided where applicable. Cochran-Mantel-
Haenszel (CMH) Chi-square tests were conducted, adjusting for gender and race when
comparing the two groups (family and internal medicine) on a binary response. All analyses
were conducted in SAS (Version 9.2, 2008; SAS Institute Inc., Cary, NC).
RESULTS
Characteristics of Respondents
Sample demographics closely mirrored population characteristics with regard to physician
gender and year of graduation (Table 1). The only discrepancy with the AMA Physician
Masterfile was specialty, with physicians in family medicine responding more frequently
than internists. Post-stratification aligned specialty to the population counts, but no other
adjustments were possible because ancillary data were not available on the AMA Physician
Masterfile. Therefore, meaningful comparisons between respondents and non-respondents
could not be made on other demographic characteristics, such as race.
Perceived Knowledge & Experience with Genetic Testing
We first asked respondents about their experience with genetic testing in general. When
asked if they felt well-informed about genetic testing, 51.4% (+/−2.25%) strongly or
somewhat disagreed. There was no significant relationship between year of graduation and
feeling well-informed (p=.195), but physicians board-certified in Family Medicine were less
likely to indicate feeling well-informed about genetic testing than internists (p=0.022). More
than half of respondents indicated that they received genetics training in medical school
(57.2+/−2.29%). Recent graduates were more likely to have indicated that they received
genetics training in medical school (p<0.0001). Most respondents (73.0% +/−2.01%)
indicated that they did not feel their genetics training adequately prepared them to
appropriately order or use genetic tests.
Haga et al. Page 3













Respondents reported ordering genetic testing for disease susceptibility or diagnosis 1–2
times per year (38.2+/− 2.23%) or 3–10 times/year (30.2% +/− 2.11%). Thirty-two percent
(+/−2.15%) indicated they have never ordered any genetic testing. When asked if they felt
comfortable ordering a genetic test to diagnose a disease, 45.7% (+/−2.24%) strongly or
somewhat agreed and 38.7% (+/−2.18%) strongly or somewhat disagreed. When asked if
they felt comfortable ordering a test to predict disease susceptibility, 38.8% (+/−2.19%)
strongly or somewhat agreed and 43.7% (+/−2.22%) strongly or somewhat disagreed. No
associations were observed between frequency of test ordering and year of graduation or
medical specialty.
PGx Testing
Most respondents (72.7+/−1.99%) reported having heard of PGx testing prior to taking the
survey. Twenty-two percent (+/−1.77%) reported not having had any form of education
about pharmacogenetics. Respondents board-certified in Family Medicine were more likely
to have had no education about pharmacogenetics compared to those board-certified in
Internal Medicine (27.9% vs. 17.0%) (p=0.003). Sixteen percent (+/− 1.63%) indicated
learning of pharmacogenetics in medical school or through their residency. Most
respondents indicated learning about pharmacogenetics through journals (46.9% +/−2.30%)
or professional meetings, CME, or grand rounds (46.61% (+/− 2.24%) %). Respondents felt
that CME (in-person courses) or grand rounds were the best way to educate physicians about
PGx testing (36.5+/−2.23%), followed by training in residency (15.5% +/−1.67%). Most
respondents (76.2+/− 2.01%) were unaware that the Food and Drug Administration had
revised drug labels to include pharmacogenetic information.
Twenty percent (+/− 1.87%) indicated that they have ordered a PGx test at least once a year;
79.6% (+/−1.92%) indicated they had never ordered a PGx test. Most respondents agreed
that PGx testing is or will soon be a valuable tool to predict risk of adverse events or
likelihood of effectiveness (64.5+/−2.21% responded strongly agree or somewhat agree).
Only 13% (+/−1.67%) of respondents felt well-informed about the role of PGx testing in
therapeutic decision-making and 67% (+/−2.20%) strongly or somewhat disagreed with the
statement that they were comfortable ordering a PGx test. Family medicine physicians were
less likely to have ordered a PGx test than internists (p=0.006). Thirty-six percent (+/
−2.06%) of respondents indicated they would be more likely to order a comparable non-
genetic PGx test (e.g., an enzyme or protein assay) if one was available.
When deciding whether or not to order a PGx test to predict likelihood of an adverse
response or determine likelihood of drug efficacy, the severity of the potential drug reaction
or the severity of the condition being treated, respectively, was considered the most
important factor, followed by the predictive value of the test, and the cost of the test (Table
2). Inclusion of pharmacogenetic information on the drug label and the test turnaround time
were considered very important by the smallest proportion of respondents.
Role of PCPs
We asked respondents to indicate which health professional or group should have primary
responsibilities for delivery of different components of PGx testing (Table 3). Overall, most
respondents (62.9+/−2.35%) believed that they should have primary responsibility for
making patients aware of a PGx test for a drug prescribed for them and for determining how
the PGx result should be recorded in the medical record (60.1+/−2.44%). There was little
recognition of other groups (with the exception of disease specialists) in the delivery of PGx
testing. They believed that a disease specialist or genetics professional should have primary
responsibility for determining which PGx variants should be included in the testing panel
(24.9+/−2.10% and 33.4+/−2.30%, respectively). Most respondents believed it was their
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responsibility as a primary care provider to discuss PGx test results with the patient (57.5+/−
2.32%), but the majority of respondents strongly or somewhat agreed (91.6+/−1.23%) that
they would refer a patient to a genetic specialist for information about familial implications.
Respondents also believed it was their responsibility to maintain a record of the patient’s
PGx test results (76.9+/−2.00%), and determine how PGx results will affect drug selection
(45.6+/−2.36%). Ten percent of respondents indicated that pharmacists should have primary
responsibility in determining the appropriate dose or drug selection based on the PGx test
result. Few significant differences in opinion existed between respondents board-certified in
internal medicine compared to family medicine.
DISCUSSION
Although PGx testing has primarily been used by clinical specialists, it is anticipated that as
the number of drugs increases for which testing becomes available, PCPs will become major
users of these tests. Therefore, we sought to understand PCPs’ training, familiarity, and
attitudes toward PGx testing in order to identify barriers to uptake that may be addressed at
this early stage of test use. We find that the primary barrier for use is PCPs’ lack of
education about PGx testing.
Supporting other findings demonstrating the low level of knowledge about
pharmacogenetics of physicians (16, 21, 23, 42) and other health professionals (43), most
respondents did not feel well-informed about PGx testing nor comfortable ordering PGx
testing. Almost a quarter reported not having any education about pharmacogenetics. Herein
lies the circularity of our and others findings: until PCPs understand how to determine which
tests should be used, what the test results mean and what actions they can take in response,
they will remain uncomfortable using PGx tests. Given the rapid developments in
pharmacogenetics, traditional educational approaches will likely need to be supplemented by
point-of-care assistance such as electronic clinical decisional supports. Although inclusion
of PGx information in the drug label was not considered a major factor by respondents in
deciding whether they would order a PGx test, more efficient delivery of drug label changes,
perhaps linked to e-prescribing databases, would improve awareness of label revisions and
use of PGx testing.
Despite the lower than anticipated use of PGx testing in general care practices (44), most
respondents’ considered PGx testing to be of value and envisioned a major role for PCPs
regarding patient education, delivery, and communication of test results. Respondents did
not recognize (or in a very limited capacity) a role for other health professionals, particularly
pharmacists and clinical geneticists, in the delivery of PGx testing. Given these two groups’
involvement in clinical research and test development, one may presume that these two
specialties would have a key role in the delivery of PGx testing as well. Indeed, both groups
have been addressing issues regarding the clinical use of PGx testing much more actively
than PCPs. During this early stage of test use, a partnership with geneticists and/or
pharmacists may be of great value to PCPs and mutually beneficial to all. PCPs should be
able to determine when testing is appropriate on their own, but collaborate with the clinical
geneticist and/or pharmacist regarding interpretation and application of results. Although
collaboration between PCPs and pharmacists has been demonstrated to improve outcomes
(45, 46), fostering these relationships has been challenging for some, which may account for
the limited recognition of this group. Pharmacy benefit managers in the U.S. have begun to
provide PGx testing to covered patients for select medications (47). We and other groups are
currently exploring the use of pharmacist-assisted delivery of PGx testing in the primary
care setting. If preemptive PGx testing and clinical decision alerts become widespread, PCPs
themselves may actually have a limited role (48). Analogous to the dual certification
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program in pathology and clinical genetics, a new combined specialty could be created
linking pharmacology and clinical genetics.
Some of our data substantially differ from a recent survey of U.S. physicians by Stanek et al.
(21). Stanek et al. reported that almost 30% of respondents received training about PGx
testing in medical school or post-graduate training, compared to 16% of our respondents.
Whereas almost 40% of respondents in their survey indicated learning about
pharmacogenetics from drug labels (21), 76% of our respondents indicated they were
unaware of drug label revisions including PGx information. With respect to test use, we
show a lower test use (ever) than reported by Stanek et al. (11.7% of internists and family
medicine physicians reported ordering a PGx test in last 6 months). These disparate findings
may be attributed to differences in the study population: Stanek et al. ’s population included
specialists, was drawn from the Medco physician database, and differences in physician age.
Furthermore, the 2-year time difference between when the surveys were conducted (2008 vs.
2010) could account for differences given the rapid pace of development in
pharmacogenetics.
Physician knowledge is but one factor influencing uptake of testing and in some cases, may
not be the major factor driving use of PGx testing. In addition to lack of knowledge, several
other factors may contribute to the low use of PGx tests, such as concern about
communicating complex test results, reimbursement, and lack of clinical guidelines (20, 49).
We found that the severity of the adverse response or condition being treated was considered
the most important factor in deciding whether to order a PGx test to predict drug response,
comporting with previous findings about perceived benefit to reduce adverse responses (32,
42). In contrast to another published study, turnaround time was not rated as highly
compared to other factors (50). Similar to other findings (20), a third of respondents
indicated they would be more likely to order a non-genetic PGx tests, perhaps due to a
combination of perceived patient concerns and physician unfamiliarity or lack of comfort
with DNA-based testing.
There were some differences between respondents board-certified in family medicine and
internal medicine. In particular, family medicine physicians were significantly more likely to
have had no education about pharmacogenetics and less likely to have ordered a PGx test
compared to internists. Substantially differing rates of use of PGx testing associated with
azathioprine have been reported, speculated to be due to different national guidelines about
test use(51). The higher knowledge and experience of internists compared to family
medicine physicians may be attributed to an older patient population with correspondingly
higher rate of drug prescription.
Some limitations of our study should be noted, specifically the low response rate. Although
respondents’ views on PGx testing may differ from PCPs as a whole due to selection bias,
their lack of confidence regarding the use of PGx and low genetic knowledge is consistent
with other data. Even if their positive expectations about the value of PGx testing represent a
minority view, our data also indicate a significant reservoir of potential early adopters.
Further study will be needed to validate our findings and determine the most appropriate and
effective methods for guidance and education.
In conclusion, our results indicate that PCPs envision a major role for themselves in the
delivery of PGx testing but recognize their lack of adequate knowledge and experience. As
the most recent survey to date, our findings suggest that educational curricula, training and
resources have not significantly advanced, have not reached or are being utilized by PCPs,
or are not effective in promoting comfort about PGx testing. Therefore, development of
effective tools for guiding PCPs in the use of PGx tests should be a high priority. In addition
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to traditional formal education in medical school and residency curricula, clinical decisional
supports and professional partnerships may be the most effective and flexible tools to
educate physicians about the use of PGx testing.
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Table 1









•    White 78.11 74.78
•    African-American 2.19 2.09
•    Asian 14.14 17.45
•    Other/Prefer Not to Answer 5.56 5.68
Hispanic 3.72 3.59
Year of Medical School Graduation
•    1980 or before 19.43 18.07
•    1981–1990 38.36 38.04
•    1991–2000 34.00 36.36
•    After 2000 8.21 7.53
Medical Specialty*
•    Family Medicine 61.08 40.58
•    Internal Medicine 37.90 58.21
•    Other 1.02 1.21
Practice Environment
   Community-based 82.23 79.17
   Hospital based 10.863 14.12
   Other 6.94 6.71
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Table 2
Comparison of perceived importance of characteristics of PGx testing to predict likelihood of adverse
response or drug efficacy (percentage).
Test Characteristic PGx testing to predict
likelihood of adverse
response1











Severity of potential drug reaction 0.78 0.16 -- --
Prevalence of the potential reaction 0.50 0.41 -- --
Likelihood of non-response -- -- 0.48 0.41
Predictive value of the test 0.58 0.31 0.57 0.32
Availability of other clinical testing to monitor drug toxicity (or drug response) 0.34 0.49 0.38 0.48
Severity of the condition being treated 0.49 0.37 0.58 0.33
Urgency of treatment -- -- 0.43 0.39
Prevalence of the genetic variant 0.37 0.43 0.34 0.51
Inclusion of information about the test on the drug label 0.18 0.32 0.19 0.33
Availability of practice guidelines 0.49 0.37 0.49 0.36
Insurance reimbursement of test 0.51 0.27 0.48 0.30
Cost of the test 0.56 0.29 0.52 0.33
Turnaround time for the test results 0.21 0.41 0.22 0.42
Cost of the drug for which the test is ordered 0.23 0.42 0.31 0.41
Availability of alternative drug .39 .46 0.36 0.48
1
Survey Question: “In your opinion, when deciding whether or not to order a PGx test to determine a potential adverse drug reaction for an
individual patient, how important are the following considerations?”
2
Survey Question: “In your opinion, when determining the value of a PGx test to identify a patient who is unlikely to respond to a drug (efficacy),
how important are the following considerations?”)
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